<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00186303</url>
  </required_header>
  <id_info>
    <org_study_id>BMT88</org_study_id>
    <secondary_id>77066</secondary_id>
    <secondary_id>BMT88</secondary_id>
    <nct_id>NCT00186303</nct_id>
  </id_info>
  <brief_title>Transplantation for Patients With Chronic Lymphocytic Leukemia</brief_title>
  <official_title>Autologous and Allogeneic Peripheral Blood Progenitor (PBPC) Transplantation for Patients With Chronic Lymphocytic Leukemia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Stanford University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Stanford University</source>
  <brief_summary>
    <textblock>
      To evaluate the role of high dose therapy and autologous or allogeneic hematopoietic cell
      transplantation for the treatment of chronic lymphocytic leukemia.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      To determine effectiveness of allogeneic transplantation in eradicating chronic lymphocytic
      leukemia.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>November 1996</start_date>
  <completion_date type="Actual">March 2010</completion_date>
  <primary_completion_date type="Actual">March 2010</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Efficacy</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Feasibility</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Toxicity</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>olymerase Chain Reaction (PCR) for minimal residual disease</measure>
  </secondary_outcome>
  <enrollment type="Anticipated">28</enrollment>
  <condition>Leukemia, Lymphocytic, Chronic</condition>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>high dose chemotherapy then autologous hematopoietic cell transplant</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>ablative allogeneic hematopoietic cell transplant</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:- adequate organ function - normal bone marrow cytogenetics

        Exclusion Criteria:- active CNS disease

        - For autologous patients more than 30% bone marrow involvement
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Robert S Negrin</last_name>
    <role>Principal Investigator</role>
    <affiliation>Stanford University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Stanford University School of Medicine</name>
      <address>
        <city>Stanford</city>
        <state>California</state>
        <zip>94305</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 13, 2005</study_first_submitted>
  <study_first_submitted_qc>September 13, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 16, 2005</study_first_posted>
  <last_update_submitted>December 13, 2012</last_update_submitted>
  <last_update_submitted_qc>December 13, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 17, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Stanford University</investigator_affiliation>
    <investigator_full_name>Robert Negrin</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Leukemia, Lymphoid</mesh_term>
    <mesh_term>Leukemia, Lymphocytic, Chronic, B-Cell</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

